TSLA
Tesla
-- 448.480 MU
Micron Technology
-- 86.200 NVDA
NVIDIA
-- 130.844 QUBT
Quantum Computing
-- 18.510 NUKK
Nukkleus
-- 62.860 
NEWS
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
Thursday, 12th December at 8:45 am
Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA's late stage pipeline
Targeting Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025
Cross product and technology synergies build on TuHURA's therapeutic focus on overcoming primary and acquired resistance to cancer immunotherapy
Proposed Transaction expected to close in Q1 2025
TAMPA, FL AND SEATTLE, WA / ACCESSWIRE / December 12, 2024 / TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kineta, Inc. (OTC: KANT) ("Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, today announced that they have entered into a definitive merger agreement in which TuHURA would acquire Kineta, including the rights to Kineta's novel KVA12123 antibody, for a combination of cash and shares of TuHURA common stock via a merger transaction (the "Proposed Transaction").
Thursday, 12th December at 8:45 am
Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA's late stage pipeline
Targeting Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025
Cross product and technology synergies build on TuHURA's therapeutic focus on overcoming primary and acquired resistance to cancer immunotherapy
Proposed Transaction expected to close in Q1 2025
TAMPA, FL AND SEATTLE, WA / ACCESSWIRE / December 12, 2024 / TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kineta, Inc. (OTC: KANT) ("Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, today announced that they have entered into a definitive merger agreement in which TuHURA would acquire Kineta, including the rights to Kineta's novel KVA12123 antibody, for a combination of cash and shares of TuHURA common stock via a merger transaction (the "Proposed Transaction").
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Nix2000 : Another merger?